Clinical Trial Search

Primary: Table 1 Study Specific Characteristic Part One — 69.8; 59.8; 59.1; 72.7 Percentage of Participants — p=>0.05

Primary: Changing LDL Cholesterol — 100; 70 Mg/dl

Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )

Primary: Change in Carotid Intima-media Thickness From Baseline to Year 1 — 0.766; 0.765; 0.758; 0.768 millmeter — p=0.7279

Primary: Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 — 40.593; 40.422; 41.013; 40.182 percent (absolute change)

Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L

Primary: Major Cardiovascular Adverse Events (MACE) — 156; 118 number of adjudicated events — p=< 0.025

Primary: The Composite of Cerebral Ischemic Stroke and Transient Ischemic Attack — 0; 0; 0; 1 Participants — p=0.462

Primary: Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week…

Primary: Сardiovascular Death — 0; 0; 0; 0 Participants

Primary: Change of Intima Media Thickness (IMT) — -0.023 mm — p=0.021

Primary: Change From Baseline in Carotid Femoral-Pulse Wave Velocity at Month 6 — 1.07; 0.99 meters per second (m/s)

Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL

Primary: Change in Necrotic Core Volume — 0.07 mm^2

Primary: Change in the Total Atheroma Volume From Baseline to 12 Weeks — -7.63; -3.10 mm^3 — p=0.2533

Primary: Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment — -0.33; 0.11 percentage of baseline

Primary: Change in the Total Atheroma Volume of the Target Coronary Artery From Baseline to 12 Weeks Post-PCI as Assessed Via Intravascular Ultrasound With Virtual Histology…

Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293

Primary: Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points — -0.3; 0.9 volume in mm cubed

Primary: Arterial Stiffness (Carotid Artery Compliance) During Saline — 1.31; 1.34; 0.90; 1.02 mm2/mm Hg×10-1

Primary: Change in Nitric Oxide Formation From Baseline to 3 Months. — 10.0; 11.2; 10.0; 11.0 ng/mL

Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation

Primary: Progression of Carotid Intima Media Thickness — 0.0062; 0.004 mm — p=0.684

Primary: Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36 — -3.14; -4.79 percent change — p=0.2279

Primary: Reduction of the Estimated 10-year Total Cardiovascular Risk Score — 11.5; 11.1 percent

Primary: Nominal Change From Baseline in Percent Atheroma Volume — 40.592; 40.016; -0.161; 0.725 Percent volume — p=0.002

Primary: Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI — -4.6; -15.1; -9.4 mm^3/year

Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001

Primary: Mean Coronary Wall Thickness — 2.0 mm

Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943